This is a note!
It contains the early rough scribblings of an article, which you could grow to a more thorough page, or simply deranged science musings! ❤
Flutamide is a nonsteroidal antiandrogen. It has been administered to transgender women in a number of studies/publications. It is used for the treatment of hirsutism at dosages ranging from 62.5 mg/day to 500 mg/day and both alone and in combination with oral contraceptives. The overall quality of the evidence for hirsutism is regarded as moderate. Flutamide may be more effective than other antiandrogens like spironolactone, cyproterone acetate, and finasteride for this indication.
Flutamide has a relatively high risk of elevated liver enzymes and hepatotoxicity and has been associated with many cases of severe hepatotoxicity, including deaths. The risk is substantially higher than with other nonsteroidal antiandrogens like bicalutamide and nilutamide. Because of its high risk of hepatotoxicity, flutamide has been recommended against for the treatment of androgen-dependent conditions like acne and hirsutism in cisgender women.
Low or ultra-low doses of flutamide have been reported to lack hepatotoxicity. However, other studies have had very different findings. In addition, many case reports of severe hepatotoxicity at low or ultra-low doses exist, including deaths.
- Giusti, M., Falivene, M. R., Carraro, A., Cuttica, C. M., Valenti, S., & Giordano, G. (1995). The effect of non-steroidal antiandrogen flutamide on luteinizing hormone pulsatile secretion in male-to-female transsexual subjects. Journal of endocrinological investigation, 18(6), 420-426.
- Falivene, M. R., Cuttica, C. M., Valenti, S., & Guido, R. (1995). Androgen receptor blockade with flutamide increases GH secretion in male-to-female transsexuals. Journal of Endocrinological Investigation, 18, 56-56.
- Valenti, S., Fazzuoli, L., & Giusti, M. (2003). Circulating nitric oxide levels increase after anti-androgen treatment in male-to-female transsexuals. Journal of endocrinological investigation, 26(6), 522-526.
- Generali, J. A., & Cada, D. J. (2014). Flutamide: hirsutism in women. Hospital pharmacy, 49(6), 517.
- Somani, N., & Turvy, D. (2014). Hirsutism: an evidence-based treatment update. American journal of clinical dermatology, 15(3), 247-266.
- Wysowski, D. K., & Fourcroy, J. L. (1996). Flutamide hepatotoxicity. The Journal of urology, 155(1), 209-212.
- Giorgetti, R., di Muzio, M., Giorgetti, A., Girolami, D., Borgia, L., & Tagliabracci, A. (2017). Flutamide-induced hepatotoxicity: ethical and scientific issues. Eur Rev Med Pharmacol Sci, 21(1 Suppl), 69-77.
- Brahm, J., Brahm, M., Segovia, R., Latorre, R., Zapata, R., Poniachik, J., ... & Contreras, L. (2011). Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Annals of hepatology, 10(1), 93-98.
- Thole, Z., Manso, G., Salgueiro, E., Revuelta, P., & Hidalgo, A. (2004). Hepatotoxicity induced by antiandrogens: a review of the literature. Urologia internationalis, 73(4), 289-295.
- García, C. M., Andrade, R. J., Lucena, M. I., Sánchez, M. H., Fernandez, M. C., Ferrer, T., ... & Montero, J. L. (2001). Flutamide-induced hepatotoxicity: report of a case series. Revista española de enfermedades digestivas: organo oficial de la Sociedad Española de Patología Digestiva, 93(7), 423-432.
- Schmidt, T. H., & Shinkai, K. (2015). Evidence-based approach to cutaneous hyperandrogenism in women. Journal of the American Academy of Dermatology, 73(4), 672-690.
- Ibanez, L., Jaramillo, A., Ferrer, A., & de Zegher, F. (2005). Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Human Reproduction, 20(7), 1833-1836.
- Legro, R. S. (2006). Long-term, low-dose flutamide does not cause hepatotoxicity in hyperandrogenic women. Nature Clinical Practice Endocrinology & Metabolism, 2(4), 188-189.
- Calaf, J., Lopez, E., Millet, A., Alcaniz, J., Fortuny, A., Vidal, O., ... & Espinos, J. J. (2007). Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. The Journal of Clinical Endocrinology & Metabolism, 92(9), 3446-3452.
- Dikensoy, E., Balat, O., Pence, S., Akcali, C., & Cicek, H. (2009). The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Archives of gynecology and obstetrics, 279(3), 321-327.
- Paradisi, R., Fabbri, R., Porcu, E., Battaglia, C., Seracchioli, R., & Venturoli, S. (2011). Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period. Gynecological Endocrinology, 27(10), 823-829.
- Bruni, V., Peruzzi, E., Dei, M., Nannini, S., Seravalli, V., Sisti, G., & Fambrini, M. (2012). Hepatotoxicity with low-and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertility and sterility, 98(4), 1047-1052.
- Castelo-Branco, C., Hernández-Angeles, C., Alvarez-Olivares, L., & Balasch, J. (2016). Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women. Gynecological Endocrinology, 32(9), 723-727.
- Castelo-Branco, C., & Del Pino, M. (2009). Hepatotoxicity during low-dose flutamide treatment for hirsutism. Gynecological Endocrinology, 25(7), 419-422.
- Osculati, A., & Castiglioni, C. (2006). Fatal liver complications with flutamide. The Lancet, 367(9517), 1140-1141.
- Amorim, M. D. F. D. D., Amorim, W. P. D. D., Duques, P., Amorim, P. D. D., & Vasconcelos, J. R. D. (2005). Flutamide-induced hepatotoxicity during treatment of acne: a case report. Anais Brasileiros de Dermatologia, 80(4), 381-384.